前收市價 | 5.30 |
開市 | 5.30 |
買盤 | 2.60 |
賣出價 | 4.40 |
拍板 | 65.00 |
到期日 | 2024-10-18 |
今日波幅 | 5.30 - 5.30 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 7 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.